Trial · NCT01426763
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 22
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site erythema | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 5 | 6 | |
| other | Injection site erythema | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 5 | 6 | |
| other | Injection site hemorrhage | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 1 | 6 | |
| other | Injection site hemorrhage | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 0 | 6 | |
| other | Injection site induration | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 0 | 6 | |
| other | Injection site induration | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 1 | 6 | |
| other | Injection site edema | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 1 | 6 | |
| other | Injection site edema | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 0 | 6 | |
| other | Injection site pain | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 4 | 6 | |
| other | Injection site pain | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 1 | 6 | |
| other | Injection site pruritus | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 1 | 6 | |
| other | Injection site pruritus | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 0 | 6 | |
| other | Injection site swelling | General disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 2 | 6 | |
| other | Injection site swelling | General disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 0 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 1 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | SC CINRYZE With rHuPH20 Dose Level 2 | 0 | 6 | |
| other | Urinary tract infection | Infections and infestations | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 0 | 6 | |
| other | Urinary tract infection | Infections and infestations | SC CINRYZE With rHuPH20 Dose Level 2 | 1 | 6 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | 0 | 6 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | SC CINRYZE With rHuPH20 Dose Level 2 | 1 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01426763/events